*Industry Talks Sessions are part of the Omnia Health Live virtual expo. To sign-up to this webinar please register for Omnia Health Live.
The novel coronavirus disease 2019 (COVID-19) is a severe systemic infectious pathology caused by acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The diagnosis of SARS-CoV-2 infection relies on direct detection (and potential quantification) of viral RNA by using reverse-transcription polymerase chain reaction (RT-PCR) in upper and lower respiratory tract specimens of suspected cases. Virus RNA can also be detected in other biological matrices such as blood, urine, stools, saliva, tears, breast milk and throat washing , but their diagnostic use remains has not been validated as yet. Serological testing provides a rather different information. According to reliable evidence, that the vast majority of COVID-19 patients develop an immune response against SARS-CoV-2, especially characterized by onset of anti-SARS-CoV-2 IgGs, between 1-2 weeks after the onset of symptoms. Their role is hence confined to demonstrate the development of an immune response against the virus once a diagnosis has been made with molecular biology and, in some dubious cases, for complementing- but not replacing - RT-PCR. The IgA and IgM response is instead more variable, and the diagnostic significance of these immunoglobulin classes remains still uncertain. Other important area of uncertainty concern the persistent neutralizing activity against the virus of anti-SARS-CoV-2 antibodies and the length of their further permanence after the infection. The availability of rapid tests for detecting either viral antigens or anti-SARS-CoV-2 antibodies represent a potential opportunity for epidemiologic surveillance, though more data would be needed on accuracy and reliability of the currently available kits.
By the end of the session, participants will learn about:
Prof. Giuseppe Lippi, MD
Full Professor of Clinical Biochemistry, Director of the Laboratory Service
University Hospital of Verona, Verona, Italy
Prof Giuseppe Lippi was born in Padova (Italy)
Degree in Medicine in 1992 and the specialization in Clinical Biochemistry and Laboratory Medicine in 1996
Full Professor of Clinical Biochemistry and Molecular Biology at the University of Verona (Italy) and Director of the Clinical Chemistry and Hematology laboratories of the University Hospital of Verona (Italy)
1700+ articles in peer-reviewed journals, his total Impact Factor is over 6550 and the Hirsch Index (H-index) is 93
600+ national and international congresses and has given more than 280 lectures to national and international meetings
In 2017 appointed Secretary of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)
Chairs Task Force on coronavirus disease 2019 (COVID-19) of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
Industry Talks Sessions are part of the Omnia Health Live virtual expo. To add this session to your calendar please register for Omnia Health Live.